|
| Ipriflavone Basic information |
| Ipriflavone Chemical Properties |
Melting point | 116-120 °C(lit.) | Boiling point | 363.04°C (rough estimate) | density | 1.2170 (rough estimate) | refractive index | 1.4700 (estimate) | storage temp. | Sealed in dry,Room Temperature | solubility | DMF:20.0(Max Conc. mg/mL);71.35(Max Conc. mM) DMF:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.71(Max Conc. mM) DMSO:33.11(Max Conc. mg/mL);118.11(Max Conc. mM) Ethanol:1.5(Max Conc. mg/mL);5.35(Max Conc. mM) | form | powder to crystal | color | White to Almost white | Merck | 14,5074 | InChI | InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 | InChIKey | SFBODOKJTYAUCM-UHFFFAOYSA-N | SMILES | C1OC2=CC(OC(C)C)=CC=C2C(=O)C=1C1=CC=CC=C1 | LogP | 4.245 (est) | CAS DataBase Reference | 35212-22-7(CAS DataBase Reference) |
| Ipriflavone Usage And Synthesis |
Description | Ipriflavone, a derivative of isoflavone, is a calcium metabolism regulator useful in the
treatment of primary and secondary osteoporosis, as well as disorders of osteogenesis. It
appears to be without significant side-effects. | Chemical Properties | white powder | Originator | Chinoin (Japan) | Uses | 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone) has been used as a model drug in a study to functionalize the mesoporous bioactive glasses (MBG). Study suggested that since ipriflavone is a hydrophobic anti-osteoporotic drug, it easily attaches to the surface of MBG and results in long-term drug delivery. | Uses | anabolic | Definition | ChEBI: Ipriflavone is a member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. It has a role as a bone density conservation agent. It is a member of isoflavones and an aromatic ether. | Brand name | Osten | General Description | 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone), a synthetic flavonoid, is reported to stimulate the activity of osteoblasts. It is reported to promote the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like (ROB) cells as well as the activity of alkaline phosphatase. Ipriflavone, an isoflavone derivative, is a new drug used to decrease bone loss in osteoporosis. | Side effects | Ipriflavone should be taken under medical supervision only. It can produce side effects such as stomach pain, diarrhoea, dizziness, etc. It may have a sudden increase in the WBC count if administered for six months or more. When the treatment with Ipriflavone is on, it is suggested that the WBC count should be monitored. |
| Ipriflavone Preparation Products And Raw materials |
|